trending Market Intelligence /marketintelligence/en/news-insights/trending/dorkxqwfm0fypfrabhzfew2 content esgSubNav
In This List

Teva launches generic version of Eisai, Helsinn's Aloxi in US

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Teva launches generic version of Eisai, Helsinn's Aloxi in US

Teva Pharmaceutical Industries Ltd. launched a generic version of Eisai Co. Ltd. and Helsinn Healthcare SA's Aloxi injection in the U.S.

Aloxi, known chemically as palonosetron hydrochloride, is used to prevent nausea and vomiting in adults after cancer chemotherapy with a moderate or high risk of causing nausea and vomiting. It is also given to prevent nausea and vomiting up to 24 hours after surgery.

In May 2017, a U.S. federal appeals court ruled, reversing a previous judgment, that the Israeli drugmaker's generic version of palonosetron does not infringe on the patents covering Aloxi to treat nausea and vomiting due to chemotherapy.

Helsinn Healthcare filed a petition for a rehearing of the patent case but the U.S. Court of Appeals for the Federal Circuit denied the motion in January.

Aloxi injection had annual sales of about $459 million in the U.S., Teva said in a news release, citing IMS data as of November 2017.